Ovivac P Plus
Active substance
ATC code
Species
Sheep.
Indications
For the active immunisation of lambs as an aid in the control of pulpy kidney, tetanus, braxy and blackleg caused by Cl.perfringens type D, Cl.septicum, Cl.tetani and Cl.chauvoei.
The vaccine may be used as an aid in the control of pneumonic pasteurellosis in sheep of all ages from a minimum age of 3 weeks and in the control of systemic pasteurellosis in weaned fattening and breeding sheep.
Dose to be administered and administration route
Dose : 2 ml
Administration: The vaccine should be administered by subcutaneous injection in the lateral side of the upper neck observing aseptic precautions.
All lambs not previously vaccinated with Ovivac P Plus must receive two injections, each of 2 ml, separated by an interval of 4 - 6 weeks. Thereafter they must receive booster injections at intervals of not more than 12 months.
On farms where the incidence of pasteurellosis is high, a supplementary booster vaccination with Ovipast Plus (Pasteurella vaccine) may be required 2 - 3 weeks prior to expected seasonal outbreaks.
Ovivac P Plus should not be used in lambs less than 3 weeks of age due to the possible immunological incompetence of the very young lamb and competition from any maternally derived colostral antibodies. Lambs born to Heptavac P Plus vaccinated ewes will, provided they receive sufficient immune colostrum during the first 1 - 2 days of life, have adequate initial levels of antibody to aid in the control of lamb dysentery, pulpy kidney, tetanus and pasteurellosis. To maintain aid in the control of pulpy kidney, tetanus and pasteurellosis, lambs being retained for late fattening or storing will require a full vaccination course of Ovivac P Plus. At a minimum age of 3 weeks these lambs should receive two injections, each of 2 ml, separated by an interval of 4 - 6 weeks.
Lambs being retained for subsequent breeding will require a full course of vaccination with a suitable breeding stock vaccine. The combined 7 in 1 Clostridial plus Pasteurella vaccine, Heptavac P Plus, is the recommended breeding stock vaccine since it provides optimal aid in the control of the predominant clostridial diseases in adult sheep by active immunisation and in young lambs by passive immunisation.
Evidence of efficacy of the Pasteurella component of Heptavac P Plus was generated in an experimental infection model and it is not possible to provide duration of immunity information using this system. There are reports that active immunity will last for up to one year and that passive immunity will persist for up to 4 weeks after birth in lambs from ewes vaccinated with conventional Pasteurella vaccines.
Heptavac P Plus, Ovivac P Plus and Ovipast Plus have been developed following research and development which resulted in the application of the ‘IRP’ technology for the manufacture of the pasteurella components of these vaccines. The inclusion of these IRP components should provide enhanced efficacy and cross protection e.g. protection against serotype A12, which is not included in the vaccine, has been demonstrated. Studies on the response of sheep to these vaccines show that two injections separated by an interval of 4-6 weeks are required to gain the full benefit of the ‘IRP’.
The vaccine bottle must be shaken well before use. Do not freeze.
The vaccine may be administered using a sterile needle and syringe, providing a fresh sterile needle is used each time the rubber cap is punctured, to avoid contamination of the remaining contents.
Syringes and needles must be from gamma irradiated packs or freshly sterilised by boiling for 20 minutes. No alcohol or other disinfectants should be used for sterilisation.
It is recommended that an automatic vaccinator is used. Since the bottle containing this product is non-collapsible the vaccinator must have a vented draw-off spike or similar device.
The instructions supplied with such syringes should be noted and care should be taken to ensure the delivery of the full dose, particularly with the final few doses from the bottle.
Adverse reactions
Occasional hypersensitivity reactions may occur.
The vaccine contains an adjuvant and, as with most adjuvanted vaccines, may result in small transient injection site reactions possibly lasting for up to 3 - 4 months after vaccination.